A biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically-relevant proteins in a highly selective manner.
Lead Underwriter
Cowen and Company, LLC, Guggenheim Securities, LLC, J.P. Morgan Securities LLC, Piper Sandler & Co
